图片: | |
---|---|
名称: | |
描述: | |
姓 名: | ××× | 性别: | 年龄: | ||
标本名称: | |||||
简要病史: | |||||
肉眼检查: |
New TNM in the Staging of Gastric Cancer
Dongfeng Tan, MD
Introduction
Properly staging cancer allows the clinician to choose the appropriate treatment modalities, reliably evaluate and predict outcomes of disease management, and uniformly document cancer cases worldwide. Although there are several classification systems for gastric cancer, the Cancer Staging Manual developed by the American Joint Committee on Cancer (AJCC) with support from International Union for Cancer Control (UICC), the American Cancer Society, American College of Surgeons, American Society of Clinical Oncology, and International Union against Cancer, is the generally accepted classification system. The cancer-staging criteria have been continually refined since 1959, with the combined efforts of medical community, and multiple medical and oncology organizations. The latest edition (7th edition) of the AJCC Cancer Staging Manual was published in early 2010. In the new edition, the AJCC and UICC used large datasets and emerging evidence to support changes in the cancer staging criteria in general, and they used data sets from Asia, Europe, and the United States for the gastric cancer staging systems in particular.
In the new edition of the AJCC staging manual, tumors arising at the EGJ, or arising within the proximal 5 cm of the stomach (cardia) that extends into the EGJ or esophagus, are staged using the TNM system for adenocarcinoma of the esophagus. All other cancers with a midpoint in the stomach lying more than 5 cm distal to the EGJ, or those within 5 cm of the EGJ but not extending into the EGJ or esophagus, are staged using the gastric cancer staging system.
DEFINITIONS OF TNM
TNM staging describes three major anatomic characteristics of cancer: 1) the location and extension of the primary tumor, 2) the presence or absence of lymph node involvement, and 3) the presence or absence of distant tumor metastasis. These features can be evaluated by physical examination, imaging studies, and histopathologic evaluation. All cancers, though, should be confirmed histologically.
Before pathologic staging, efforts should be made to differentiate primary gastric cancer from metastatic disease, which is not an uncommon event. After the primary gastric cancer is established, gastric cancer should be classified. Majority of gastric cancer is adenocarcinoma. The histological subtypes of gastric cancer are listed in Table 1.
Table 1. The histological subtypes of gastric cancer
------------------------------------------------------
Adenocarcinoma (more than 90%)
Adenosquamous carcinoma
Mucinous adenocarcinoma
Papillary adenocarcinoma
Signet ring cell carcinoma
Squamous cell carcinoma
Tubular adenocarcinoma
Undifferentiated carcinoma
-------------------------------------------------------
Pathologically, the extent of the tumor needs to be carefully assessed. Pathologic staging depends on data acquired clinically together with findings on subsequent gross and microscopic examination of the surgically resected specimen.
Of note, the TNM staging recommendations apply only to carcinomas. Lymphomas, sarcomas, and carcinoid tumors (well-differentiated neuroendocrine tumors) are excluded. Mixed glandular/neuroendocrine carcinomas should be staged using the gastric carcinoma staging system for well-differentiated gastrointestinal neuroendocrine tumors.
Designation of primary gastric cancer status
Staging of primary gastric adenocarcinoma is dependent on the extension and depth of penetration of the primary tumor. Histologically, the wall of the stomach has five layers: mucosa, submucosa, muscular propria, subserosal connective tissue, and serosal surface.
One of the major changes to the T designation for gastric cancer in the 7th edition of the AJCC Cancer Staging Manual is that the T categories have been modified to correspond to the T categories for cancers of the esophagus and small and large intestine. Specifically, T1 lesions have been subdivided into T1a and T1b, which are defined as tumor invades muscularis mucosae and tumor invades submucosa, respectively; T2 is defined as a tumor that invades the muscularis propria; T3 is defined as a tumor that invades the subserosal connective tissue (formerly T2b in AJCC Cancer Staging Manual, 6th edition); and T4 is defined as a tumor that invades the serosa (visceral peritoneum, formerly T3 in AJCC Cancer Staging Manual, 6th edition) or adjacent structures. The T (primary tumor) designation of gastric cancer is listed in Table 2.
Table 2. Primary Tumor (T) of Gastric Cancer
________________________________________________________________________
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ: intraepithelial tumor without invasion of the lamina propria
T1 Tumor invades lamina propria, muscularis mucosae, or submucosa
T1a Tumor invades lamina propria or muscularis mucosae
T1b Tumor invades submucosa
T2 Tumor invades muscularis propria
T3 Tumor penetrates subserosal connective tissue without invasion of visceral peritoneum or adjacent structures *
T4 Tumor invades serosa (visceral peritoneum) or adjacent structures *
T4a Tumor invades serosa (visceral peritoneum)
T4b Tumor invades adjacent structures
________________________________________________________________________
*The adjacent structures of the stomach include the spleen, transverse colon, liver, diaphragm, pancreas, abdominal wall, adrenal gland, kidney, small intestine, and retroperitoneum.
Designation of regional lymph node status
The regional lymph nodes of the stomach are roughly divided into two major groups: 1) the perigastric nodes, which include nodes in the greater curvature of the stomach and nodes in the lesser curvature of the stomach, and 2) the local nodes in the pancreatic and splenic area.
Adequate dissection of these regional nodal areas is important to ensure the appropriate pN designations and final staging. For pathologic assessment, the regional lymph nodes are removed and examined histologically to evaluate the total number of lymph nodes as well as the number that contain metastatic tumors. N categories have been modified in the new AJCC staging manual, with N1=1-2 positive regional lymph nodes, N2=3-6 positive regional lymph nodes (N1 in the 6th edition of AJCC staging manual) and N3=7 or more positive regional lymph nodes. In addition, metastatic nodules in the fat adjacent to a gastric carcinoma, without evidence of residual lymph node tissue, are considered regional lymph node metastases. Although it has been suggested that pathologists assess at least 16 regional lymph nodes, a pN determination may be assigned on the basis of the actual number of nodes evaluated microscopically. The N (regional lymph node) designation of gastric cancer is listed in Table 3.
Table 3. Regional Lymph Nodes (N) of Gastric Cancer
________________________________________________________________________
NX Regional lymph node(s) cannot be assessed
N0 No regional lymph node metastasis*
N1 Metastasis in 1-2 regional lymph nodes
N2 Metastasis 3-6 regional lymph nodes
N3 Metastasis in seven or more regional lymph nodes
N3a Metastasis in 7-15 regional lymph nodes
N3b Metastasis in 16 or more regional lymph nodes
________________________________________________________________________
*Note: A designation of pN0 should be used if all examined lymph nodes are negative, regardless of the total number removed and examined.
Designation of distant metastasis status:
Two designations of metastatic status are included in the 7th edition of the AJCC Cancer Staging Manual, namely, M0: No distant metastasis, and M1:Distant metastasis. Note, no Mx designation was mentioned in the 7th edition of the AJCC Cancer Staging Manual.
Distant metastasis means that the tumor has disseminated to distant lymph nodes or a distant organ system. The distant lymph nodes of gastric cancer include retropancreatic, hepatoduodenal, para-aortic, portal, retroperitoneal, and mesenteric. Involvement of these intra-abdominal lymph nodes is classified as distant metastasis. Other metastatic sites include distant organs (liver, lungs, and central nervous system) and peritoneal surfaces (tumor implants). Positive peritoneal cytology is now classified as metastatic disease (M1). A summary of designation of distal metastatic tumor is listed in Table 4.
Table 4. Designation of distal metastatic tumor (M1)
--------------------------------------------------------
Metastatic carcinoma in distant lymph nodes
Hepatoduodenal
Mesenteric
Para-aortic
Portal
Retropancreatic
Retroperitoneal
Metastatic carcinoma in distant organs
Liver
Lungs
CNS
Other less common organ sites
Metastatic carcinoma in peritoneal surfaces
Metastatic carcinoma in peritoneal cytology
----------------------------------------------------
DESIGNATION OF ANATOMIC STAGE
The final grouping (staging) of gastric cancer is dependent on the appropriate designations of T, N, and M. The anatomic stage, based on the current AJCC Cancer Staging Manual, is listed in Table 5. Of note, if there is uncertainty concerning the appropriate T, N, or M designation, the lower (less advanced) category should be assigned, in accordance with the general rules of staging.
Table 5 Anatomic Stage of Gastric Cancer*
_______________________________________________________________________
Stage 0 Tis N0 M0
Stage IA T1 N0 M0
Stage IB T2 N0 M0
T1 N1 M0
Stage IIA T3 N0 M0
T2 N1 M0
T1 N2 M0
Stage IIB T4a N0 M0
T3 N1 M0
T2 N2 M0
T1 N3 M0
Stage IIIA T4a N1 M0
T3 N2 M0
T2 N3 M0
Stage IIIB T4b N0 M0
T4b N1 M0
T4a N2 M0
T3 N3 M0
Stage IIIC T4b N2 M0
T4b N3 M0
T4a N3 M0
Stage IV
Any T AnyN M1
________________________________________________________________________
* from the AJCC Cancer Staging Manual, 7th Edition.
xuelang312 离线
yyp8214136 离线
yanjinputao 在线
liziqiang88 离线